Therapy duration and improvement of ventricular function in de novo heart failure: the Heart Failure Optimization study

Author:

Veltmann Christian12ORCID,Duncker David1ORCID,Doering Michael3ORCID,Gummadi Siva4,Robertson Michael5,Wittlinger Thomas6,Colley Byron J7,Perings Christian8,Jonsson Orvar9,Bauersachs Johann1ORCID,Sanchez Robert10,Maier Lars S11ORCID

Affiliation:

1. Department of Cardiology and Angiology, Hannover Medical School , Carl-Neuberg-Str. 1, 30625 Hannover , Germany

2. Heart Center Bremen, Electrophysiology Bremen , Senator-Wessling-Str. 1, 28277 Bremen , Germany

3. Heart Center Leipzig, University of Leipzig , Leipzig , Germany

4. Department of Cardiology, CVI of Central Florida , Ocala, FL , USA

5. Department of Cardiology, Trinity Medical, WNY , Buffalo, NY , USA

6. Department of Cardiology, Asklepios Harzklinik Goslar , Goslar , Germany

7. Department of Cardiology, Jackson Heart Clinic , Jackson, MS , USA

8. Department of Cardiology, Katholisches Klinikum Luenen , Luenen , Germany

9. Department of Cardiology, Sanford Cardiovascular Institute , Sioux Falls, SD , USA

10. Department of Cardiology, HCA Florida Heart Institute , St. Petersburg, FL , USA

11. Department of Internal Medicine II, University Hospital Regensburg , Regensburg , Germany

Abstract

Abstract Background and Aims In patients with de novo heart failure with reduced ejection fraction (HFrEF), improvement of left ventricular ejection fraction (LVEF) is expected to occur when started on guideline-recommended medical therapy. However, improvement may not be completed within 90 days. Methods Patients with HFrEF and LVEF ≤ 35% prescribed a wearable cardioverter-defibrillator between 2017 and 2022 from 68 sites were enrolled, starting with a registry phase for 3 months and followed by a study phase up to 1 year. The primary endpoints were LVEF improvement > 35% between Days 90 and 180 following guideline-recommended medical therapy initiation and the percentage of target dose reached at Days 90 and 180. Results A total of 598 patients with de novo HFrEF [59 years (interquartile range 51–68), 27% female] entered the study phase. During the first 180 days, a significant increase in dosage of beta-blockers, renin–angiotensin system inhibitors, and mineralocorticoid receptor antagonists was observed (P < .001). At Day 90, 46% [95% confidence interval (CI) 41%–50%] of study phase patients had LVEF improvement > 35%; 46% (95% CI 40%–52%) of those with persistently low LVEF at Day 90 had LVEF improvement > 35% by Day 180, increasing the total rate of improvement > 35% to 68% (95% CI 63%–72%). In 392 patients followed for 360 days, improvement > 35% was observed in 77% (95% CI 72%–81%) of the patients. Until Day 90, sustained ventricular tachyarrhythmias were observed in 24 wearable cardioverter-defibrillator carriers (1.8%). After 90 days, no sustained ventricular tachyarrhythmia occurred in wearable cardioverter-defibrillator carriers. Conclusions Continuous optimization of guideline-recommended medical therapy for at least 180 days in HFrEF is associated with additional LVEF improvement > 35%, allowing for better decision-making regarding preventive implantable cardioverter-defibrillator therapy.

Funder

Zoll Cardiac Management Solutions

Publisher

Oxford University Press (OUP)

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3